GP IIb/IIIa receptor antagonists ? molecular and clinical aspects

• Authors: T. Francuz
• Languages of publication: EN

Abstracts

EN

Recently many investigators have found that platelet glycoprotein GP IIb/IIIa is responsible for platelet aggregation and plays a pivotal role in acute coronary thrombosis. Thus, GP IIb/IIIa antagonists may play an important role by inhibiting platelet aggregation and their binding to fibrinogen. Drugs that antagonize this binding have been developed for the treatment of thrombotic diseases and acute coronary syndrome. Now, there are three group of platelet receptor antagonists: monoclonal antibodies, synthetic peptides and non-peptide antagonists. As a result of large clinical trials the potency of those compounds in preventing of coronary thrombosis have been demonstrated. In this article molecular aspects of GP antagonists action and selected clinical trials have been presented.

Keywords

EN

AGGREGATION   ARACHIDONIC ACID   CORONARY ANGIOPLASTY   PLATELET FACTOR   TISSUE FACTOR   TROMBOXANE A2  

Discipline

• EXPERIMENTAL_BIOLOGY_&_MEDICINE: EXPERIMENTAL BIOLOGY & MEDICINE

• Publisher: Index Copernicus International; Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
• Journal: Postępy Higieny i Medycyny Doświadczalnej
• Year: 2001
• Volume: 55
• Issue: 3
• Pages: 419-432
• Document Type: ARTICLE
• Publication order reference: T. Francuz, ul. Gliwicka 218a/1, 40-860 Katowice, Poland